370 related articles for article (PubMed ID: 30640687)
1. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer.
Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB
Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687
[TBL] [Abstract][Full Text] [Related]
2. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.
Hwang JY; Kim DH; Bae HS; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Kim MK
Int J Gynecol Cancer; 2017 May; 27(4):738-742. PubMed ID: 28346240
[TBL] [Abstract][Full Text] [Related]
3. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
[TBL] [Abstract][Full Text] [Related]
4. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
5. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer.
Park JY; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
Obstet Gynecol; 2013 Jan; 121(1):136-42. PubMed ID: 23262938
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Kanao H; Kondo E; Takeshima N
Arch Gynecol Obstet; 2016 Jan; 293(1):177-181. PubMed ID: 26209972
[TBL] [Abstract][Full Text] [Related]
8. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
[TBL] [Abstract][Full Text] [Related]
9. Continued medical treatment for persistent early endometrial cancer in young women.
Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662
[TBL] [Abstract][Full Text] [Related]
10. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
11. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
12. Fertility sparing treatment in patients with endometrial cancer (FERT-ENC): a multicentric retrospective study from the Spanish Investigational Network Gynecologic Oncology Group (SPAIN-GOG).
Lago V; Marina T; Laseca Modrego M; Gil-Ibañez B; Rodriguez JR; Domingo J; Minig L; Padilla-Iserte P; Arencibia Sánchez O; Sala Ferichola M; Munmanny M; Martín Salamanca B; Iacoponi S; Cabrera S; Coronado P; Utrilla-Layna J; Bataller Á; Fiol G; Corbalán S; Espinosa E; Gil-Moreno A; Domingo S;
Arch Gynecol Obstet; 2022 Sep; 306(3):821-828. PubMed ID: 35122158
[TBL] [Abstract][Full Text] [Related]
13. Fertility-sparing hormonal treatment in patients with stage I endometrial cancer of grade 2 without myometrial invasion and grade 1-2 with superficial myometrial invasion: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-2001).
Lee AJ; Yang EJ; Kim NK; Kim Y; Suh DH; Kim J; Son JH; Kong TW; Chang SJ; Hwang DW; Park SJ; Kim HS; Yoo JG; Lee SJ; Lee YY; Shim SH
Gynecol Oncol; 2023 Jul; 174():106-113. PubMed ID: 37172410
[TBL] [Abstract][Full Text] [Related]
14. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
15. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH
Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687
[TBL] [Abstract][Full Text] [Related]
16. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
He Y; Wang Y; Zhou R; Wang J
Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
[TBL] [Abstract][Full Text] [Related]
17. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
[TBL] [Abstract][Full Text] [Related]
19. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
20. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
